HER2 and ER are the main drivers of cell proliferation and survival in BC [54], and bi-directional crosstalk can lead to cooperation between these two pathways in HER2+, ER+ BC (Fig. 1) and development of treatment resistance; moreover, inhibition of one pathway leads to upregulation of the other [48, 54, 55]. Here, ERBB2 is linked to breast cancer.